An international research team has identified Apilimod as a compound that blocks the Hepatitis E virus from entering human liver cells by targeting the host enzyme PIKfyve.
Apilimod prevents viral entry by inhibiting a cellular transport enzyme
The study, published in eGastroenterology on March 31, 2026, found that PIKfyve plays a central role in the endolysosomal system, which Hepatitis E virus uses to infect cells. Apilimod, a known PIKfyve inhibitor, efficiently prevented virus entry in cell cultures, primary human liver cells, and a rat model.
Targeting host factors reduces resistance risk compared to direct antivirals
Unlike traditional antivirals that attack the virus directly, Apilimod blocks a cellular mechanism the virus depends on, lowering the chance of resistance development, according to co-authors Sarah Schlienkamp and Julian Ring. The compound showed antiviral effects without significantly disrupting core cell functions in tested systems.
Prior clinical testing of Apilimod could speed hepatitis E treatment development
Apilimod has already undergone clinical investigation for other conditions, giving it an established safety profile that may accelerate its repurposing for Hepatitis E, noted co-author Maria Darido. Researchers emphasize the approach supports broader therapeutic strategies targeting host factors rather than viral components.
What is Hepatitis E and how is it currently treated?
Hepatitis E is a viral liver infection spread through contaminated water or undercooked meat, causing acute illness; no specific antiviral treatment is currently approved, with management focusing on supportive care.
Why does targeting a host enzyme like PIKfyve reduce resistance concerns?
Because the virus cannot easily mutate to bypass a human cellular mechanism it relies on for entry, unlike changes to viral proteins that direct antivirals target.
Auch interessant
